Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza-Reference-Cited by-同舟云学术

Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza

Published:2005-11 Issue:3 Volume:34 Page:170-178
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Savarino Andrea

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference33 articles.

1. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs;Anand;Science,2003

2. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors;Cassone;J Infect Dis,1999

3. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study;Chan;Hong Kong Med J,2003

4. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome;Chen;Clin Infect Dis,2004

5. Lack of severe acute respiratory syndrome in 19 AIDS patients hospitalised together;Chen;J Acquir Immun Defic Syndr,2003

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of artificial intelligence (AI) to control COVID-19 pandemic: Current status and future prospects;Heliyon;2024-02

2. Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro;Antiviral Research;2024-01

3. Broad-spectrum antiviral activity of clinically approved CYP3A inhibitors against pathogenic human coronaviruses in vitro;2023-08-23

4. Liposomal Delivery of Saquinavir to Macrophages Overcomes Cathepsin Blockade by Mycobacterium tuberculosis and Helps Control the Phagosomal Replicative Niches;International Journal of Molecular Sciences;2023-01-06

5. A guide to COVID ‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV ‐2 infection;The FEBS Journal;2022-11-05